Cancer-related inflammation is associated with tumour proliferation, maintenance and dissemination. It therefore impacts pancreatic cancer survival. The goal of this study was to examine the Prognostic Index (PI) as a prognostic biomarker for survival in patients with pancreatic ductal adenocarcinoma (PDAC). In addition, we explored factors known to interact with the immune and inflammation cascade that might interfere with the PI’s strength for prognostication.
Methods
Patients with PDAC undergoing resection were analysed retrospectively. The PI was calculated from preoperatively derived C-reactive protein levels and white blood count. Data were subject to correlation and survival analysis.
Results
Of 357 patients, 235 (65.8%) patients had a PI 0, 108 (30.3%) PI 1, and 14 (3.9%) PI 2. Median (quartiles) survival with a high PI (group 1 + 2) was 13.2 months (7.7–27.0), compared with 18.7 months (10.2–35.4) with a low PI (group 0; p = 0.012). The PI proved to be an independent prognostic factor for cancer-specific survival (p = 0.003) adjusted for conventional prognostic factors. Prognostic strength was influenced by the presence of a bile stent (p = 0.032).
Conclusions
The PI is a strong and solid independent prognostic tool for survival in patients with PDAC undergoing resection. Preoperative survey of inflammatory activity as provided by the use of a biomarker like the PI may help to identify those patients at risk of a poor prognosis.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Pancreatic ductal adenocarcinoma (PDAC) remains one of the solid malignancies with a poor prognosis despite some improvements gained over the course of centuries past. This is because the majority of patients were diagnosed with a locally advanced or metastatic disease.1 One key factor for adequate treatment is reliable, detailed knowledge of the actual extent of disease and the patient’s condition at initial diagnosis. To date, this was based mainly on the radiographic description of vascular involvement by the tumour and the presence of distant metastases. Recently, factors reflecting tumour biology, such as CA19-9 serum concentration and suspected lymphadenopathy as well as patients’ condition, were added to the clinical estimation of disease stage and outcome.2–5 However, the body’s inflammatory response to the presence of a malignancy was frequently neglected, despite that it showed a significant impact on outcome in PDAC.6–10
Among a wide range of inflammatory mediators, cytokines stimulate tumour development at different stages from tumourigenesis to dissemination. In addition, they affect treatment response and are associated with rapid deterioration and a dismal prognosis.11–14 In clinical practice, this is simply reflected by the production of acute phase proteins, such as C-reactive protein (CRP) and the increase of circulating blood leucocytes.15,16 The link between systemic inflammation and tumour behaviour implies the identification of clinically available surrogate markers to determine the extent of the disease.17–19
Anzeige
The Prognostic Index (PI) was first described in a cohort of patients with advanced non-small-cell lung cancer, where it showed a significant value for survival prognosis. The PI can easily be calculated from CRP serum concentration and white blood count (WBC) derived preoperatively.20 Yet, its impact on survival in a selected cohort of patients with PDAC undergoing resection has not been investigated to date.
The purpose of the present study was to assess the utility of the PI as a prognostic biomarker for cancer-specific survival in patients with PDAC undergoing resection with due regard to well-established prognostic factors, such as CA19-9 and tumour stage. We further intended to assess whether factors that interact with the immune and inflammation cascade might interfere with the PI’s strength for survival prognostication.21–31
Methods
Study Cohort
The study cohort consisted of patients with PDAC who underwent pancreatic resection at a tertiary referral University hospital. Patients were prospectively entered into an institutional database and followed over time. Data analysis was retrospectively performed, including only those patients who successfully underwent pancreatic resection. Patients with borderline resectable disease who received neoadjuvant chemo- or (radio-)chemotherapy of various protocols also were included.5 Hereby, all patients completed the full course of neoadjuvant therapy. Patient follow-up was completed by August 2017. Histopathological tumour characteristics were determined according to the AJCC/UICC TNM staging system of resected surgical specimen.32 Patients with any kind of obvious infection 6 weeks before surgery as well as patients with distant metastases (AJCC/UICC stage IV) were excluded from the study. Examinations were conducted in accordance with the Helsinki declaration. Approval was obtained from the local Ethics Committee (EK-Nr. 1166/2013).
Calculation of the Prognostic Index
The Prognostic Index (PI) combines C-reactive protein (CRP) and white blood cell count (WBC), which were routinely measured during preoperative evaluation 2 days before resection, when patients were admitted for surgery. Following the previous description, patients were divided into three PI groups as summarized in Table 1.20 CRP serum concentration was measured automatically by Cobas® 8000 modular analyser series (Roche®), with normal levels below 10 mg/L. WBC was analysed by Sysmex® XE-5000 (Sysmex®), normal range 4.0 to 10.0 G/L.
Table 1
Definition of the Prognostic Index consisting of preoperative C-reactive protein and white blood count
Patient and Tumour Characteristics in Relation to the PI
Medical records of 357 patients who underwent pancreatic resection for PDAC were analysed. Patient and tumour characteristics are shown in Table 2. Of the 357 patients comprising the study cohort, 235 (72.1%) patients underwent pylorus-preserving pancreaticoduodenectomy, and in 72 (23.5%) patients, distal pancreatectomy was performed. Tumour stage was distributed as follows: 13 patients had stage IA, 25 patients stage IB, 45 patients stage IIA, 255 patients stage IIB, and 19 patients stage III disease according to UICC/AJCC TNM staging system.32 Hence, 274 of 357 (76.8%) had a nodal-positive disease. Patients with borderline or locally advanced PDAC were referred to neoadjuvant therapy; depending on the patients’ condition, either bevacizumab, 5-fluorouracil-, or gemcitabine-based protocols were given. Of the 50 patients who received neoadjuvant therapy, 41 patients (82.0%) received gemcitabine-based therapy, and 9 (18.0%) patients received 5-fluorouracil-based therapy. During a median follow-up time of 100.5 (range 0–198) months, 333 (93.3%) patients died from their disease or disease-related complications; only 2 patients died within a median length of hospital stay of 12 days (± 4 days). The median cancer-specific survival time was 16.5 (range 0.2–198) months. PI score groups were distributed as follows: PI 0 if CRP ≤ 10 mg/L and WBC ≤ 11 × 109; PI 1 if one of the two markers was elevated; and PI 2 if both markers were elevated (Table 1). The relation of the PI, with patient and tumour characteristics, is shown in Table 2. In addition, WBC was significantly higher in patients with a positive smoking history (p = 0.004), but not in patients with a history of diabetes (p = 0.36), and did not correlate with tumour stage (UICC, rs = 0.07, p = 0.19). Patients with nodal-positive disease did not differ with respect to WBC compared with nodal-negative patients (p = 0.42; data not shown). Furthermore, CRP did not correlate with the patients’ smoking history (p = 0.90). With respect to neoadjuvant therapy, all patients with a PI of 2 (n = 2, 100.0%) received a gemcitabine-based regimen, while patients with a PI of 1 and 0 received 5-fluorouracil- or gemcitabine-based regimen (PI 1: n = 1, 14.3% or n = 6, 85.7%; PI 0: n = 8, 19.5% or n = 33, 80.5%). We found no significant difference in the PI between the two groups of neoadjuvant therapy regimens given (p = 0.55).
Table 2
Patient and tumour characteristics in relation to the Prognostic Index
Factors
PI group 0
PI group 1
PI group 2
p-value
Study cohort
357 (100)
235 (65.8)
108 (30.3)
14 (3.9)
Sex
0.17*
Male, n (%)
186 (52.1)
117 (49.8)
59 (54.6)
10 (71.4)
Female, n (%)
171 (47.9)
118 (50.2)
49 (45.4)
4 (28.6)
Age
rs = 0.06** (0.25)
Median (range)
76 (37–101)
76 (47–101)
77 (37–97)
74 (62–93)
Diabetes
0.74*
Yes, n (%)
80 (22.4)
55 (23.4)
19 (17.6)
6 (42.9)
No, n (%)
277 (77.6)
180 (76.6)
89 (82.4)
8 (57.1)
Smoking history
0.17*
Yes, n (%)
153 (42.9)
94 (40.0)
54 (50.0)
5 (35.7)
No, n (%)
204 (57.1)
141 (60.0)
54 (50.0)
9 (64.3)
Bile stent
0.56*
Yes, n (%)
172 (48.2)
115 (48.9)
53 (49.1)
4 (28.6)
No, n (%)
185 (51.8)
120 (51.1)
55 (50.9)
10 (71.4)
Neoadjuvant therapy
0.01*
Yes, n (%)
50 (14.0)
41 (17.5)
7 (6.5)
2 (14.3)
No, n (%)
307 (86.0)
194 (82.5)
101 (93.5)
12 (85.7)
Neoadjuvant tx protocol
0.55*
Gemcitabine-based tx
41 (82.0)
33 (80.5)
6 (85.7)
2 (100.0)
5-fluorouracil-based tx
9 (18.0)
8 (19.5)
1 (14.3)
0 (0.0)
Preoperative bilirubin
rs = 0.22** (p < 0.0001)
Median (range)
1.10 (0–68)
0.81 (0–68)
2.02 (0–48.9)
0.93 (0.2–17.9)
Preoperative CA 19-9
rs = 0.07** (p = 0.19)
Median (range)
133 (0–10,280)
125.1 (0–10,280)
141.7 (0–2837)
319.9 (4.6–2995)
Type of surgery
0.69*
PPPD
235 (72.1)
129 (42.0)
98 (31.9)
8 (2.6)
DP
72 (23.5)
37 (12.1)
31 (10.1)
4 (1.3)
Tumour grading
rs = − 0.002** (p = 0.97)
Good (G1), n (%)
15 (4.2)
10 (4.3)
4 (3.7)
1 (7.1)
Moderate (G2), n (%)
225 (63.0)
148 (63.0)
68 (63.0)
9 (64.3)
Poor (G3), n (%)
117 (32.8)
77 (32.7)
36 (33.3)
4 (28.6)
AJCC/UICC stage
rs = 0.12** (p = 0.03)
< IIB, n (%)
83 (23.2)
62 (26.4)
18 (16.7)
3 (21.4)
≥ IIB, n (%)
274 (76.8)
173 (75.6)
90 (83.3)
11 (78.6)
Resection margin
rs = 0.009** (p = 0.86)
Negative (R0), n (%)
286 (80.1)
188 (80.0)
89 (82.4)
9 (64.3)
Positive (R1 + 2), n (%)
71 (19.9)
47 (20.0)
19 (17.6)
5 (35.7)
Bold values are statistically significant (p-value < 0.05)
Survival Analysis, Prognosis Estimation, and Interaction Model
Comparison of the PI groups using Kaplan–Meier curves showed significantly different survival times (p = 0.044; Fig. 1a). When comparing pooled analysis between patients without elevated inflammatory factors (PI 0) and patients with elevated inflammatory factors (PI 1 and 2), the differences in survival were higher (p = 0.012, Fig. 1b). Median (quartiles) patient survival with a high PI (group 1 + 2) was 13.2 months (7.7–27.0) compared with 18.7 months (10.2–35.4) in patients with a low PI (group 0). Univariate Cox-Regression analysis confirmed that the PI had a significant impact on survival (p = 0.013) where the risk for cancer-specific death was 1.33 times higher (CI 1.06–1.67; data not shown) in the group with a high PI (PI 1 + 2 vs. PI 0). When including the PI into a multivariable Cox-Regression model in addition to established prognostic factors and factors that interfered with the immune and inflammation cascade, the PI proved to be a strong and independent prognostic factor for survival (p = 0.003) next to tumour grading (p = 0.009), age (p = 0.019) and neoadjuvant therapy (p = 0.0009; Table 3). Furthermore, the interaction terms were included in the multivariable model; what became evident was that the presence of a bile stent had an influence on the strength of the PIs survival prognosis (p = 0.032; Table 4). For patients without a bile stent, the hazard ratio was estimated as 1.13 (CI 0.81–1.57), whereas a hazard ratio of 1.87 (CI 1.34–2.61) was estimated for patients with a bile stent (data not shown). To test whether advanced disease has to be treated as a separate entity with respect to the PI, we performed a sensitivity analysis in a cohort of 307 patients with primary resectable PDAC only; we found that the PI had a significant impact on survival (p = 0.007); the risk of cancer-specific death was 1.40 times higher (CI 1.10–1.78; data not shown) in the group with a high PI (PI 1 + 2 vs. PI 0). Included in the multivariable Cox-Regression model, the PI persisted as a strong independent prognostic factor for postoperative survival (p = 0.007) next to tumour grading (p = 0.016) and stage (p = 0.009; Table 5). When including the interaction terms into the multivariable model, again the presence of a bile stent had an influence on the strength of the PIs survival prognosis (p = 0.018) in contrast to the other concomitant factors (Table 6).
Fig. 1
a Kaplan–Meier survival curves for PI groups: high preoperative PI score impairs survival in patients with resectable PDAC (PI 0 vs. PI 1. vs. PI 2, p = 0.044). b Kaplan–Meier survival curves for PI groups: high preoperative PI score impairs survival in patients with resectable PDAC (PI 0 vs. PI 1 + 2, p = 0.012)
Table 3
Cox-Regression analysis in PDAC patients undergoing resection (n = 357)
Pre-/postoperative factor
Univariate analysis
Multivariable model
p-value
p-value
Hazard ratio
95% Confidence interval
Prognostic Index
(1 + 2 vs. 0)
0.013
0.003
1.44
1.13–1.83
Tumour grading
0.019
0.009
1.32
1.07–1.62
AJCC/UICC stage
0.053
0.124
1.12
0.97–1.29
Age
0.079
0.019
1.01
1.00–1.02
Diabetes
0.178
0.086
1.26
0.97–1.65
Smoking history
0.514
0.408
1.10
0.88–1.37
Bile stent
0.717
0.528
1.07
0.86–1.34
Neoadjuvant tx
0.046
0.0009
1.73
1.25–2.40
Preoperative bilirubin
(log2-transformed)
0.654
0.582
0.99
0.94–1.04
Preoperative CA 19-9
(log2-transformed)
0.138
0.070
1.03
1.00–1.07
Resection margin
0.048
0.029
1.36
1.03–1.79
Bold values are statistically significant (p-value < 0.05)
Table 4
Interaction terms considered for inclusion in the multivariable Cox-Regression model
Pre-/postoperative factor
p-value
PI * Tumour grading
0.871
PI * AJCC/UICC stage
0.334
PI * Age
0.227
PI * Diabetes
0.066
PI * Smoking history
0.563
PI * Bile stent
0.032
PI * Neoadjuvant tx
0.663
PI * Preoperative bilirubin
0.740
PI * Preoperative CA 19-9
0.225
PI * Resection margin
0.351
Bold values are statistically significant (p-value < 0.05)
Table 5
Cox-Regression analysis in patients with primary resectable PDAC (borderline resectable/locally advanced PDAC excluded; n = 307)
Pre-/postoperative factor
Univariate analysis
Multivariable model
p-value
p-value
Hazard ratio
95% Confidence interval
Prognostic Index
(1 + 2 vs. 0)
0.007
0.007
1.43
1.11–1.85
Tumour grading
0.011
0.016
1.33
1.06–1.68
AJCC/UICC stage
0.003
0.009
1.26
0.06–1.51
Age
0.080
0.023
1.01
1.00–1.02
Diabetes
0.105
0.051
1.33
1.00–1.77
Smoking history
0.690
0.450
1.10
0.87–1.40
Bile stent
0.766
0.482
1.09
0.86–1.39
Preoperative bilirubin
(log2-transformed)
0.252
0.910
1.00
0.94–1.06
Preoperative CA 19-9
(log2-transformed)
0.174
0.143
1.03
1.00–1.07
Resection margin
0.056
0.073
1.30
0.98–1.74
Bold values are statistically significant (p-value < 0.05)
Table 6
Interaction terms considered for inclusion in the multivariable Cox-Regression model
Pre-/postoperative factor
p-value
PI * Tumour grading
0.829
PI * AJCC/UICC stage
0.138
PI * Age
0.265
PI * Diabetes
0.074
PI * Smoking history
0.497
PI * Bile stent
0.018
PI * Preoperative bilirubin
0.702
PI * Preoperative CA 19-9
0.212
PI * Resection margin
0.426
Bold values are statistically significant (p-value < 0.05)
×
Discussion
The present study assessed the preoperative conducted PI applicability for survival prognostication in patients with PDAC undergoing resection. The PI was found to be a strong independent prognostic factor for survival that was superior to other prognostic factors, such as tumour grade, stage, and CA 19-9. In this analysis, of all concomitant factors that interact with the immune and inflammation cascade, the presence of a bile stent was the only factor that influenced the PI’s strength for survival prognostication.21–31
Prognosis estimation in PDAC patients undergoing resection mainly relies on postoperative available factors. The AJCC/UICC tumour stage, which becomes available only after histopathological reworking, provides the basis for subsequent treatment decisions.2,32 To date, postoperative survival is not routinely estimated before treatment of PDAC. CA 19-9 is the only biomarker available for prognostication, yet the high specificity limits its utility and definitive applicability with respect to treatment response can only be determined during treatment course in terms of marker decrease.34 In addition, we show that the PI proves highly significant as an independent prognostic factor in contrast to CA 19-9. Consequently, the investigation of screening biomarkers that can be reliantly applied before surgery is of the utmost importance.
Cancer-related inflammation is a hallmark of cancer.35 Next to tumour proliferation, maintenance and dissemination, it promotes angiogenesis, disarrangement of adaptive immunity as well as impaired chemotherapy response.36 Accordingly, specific scores have been established on the basis of inflammatory markers that have been validated as prognosticators of therapy response and outcome in patients with solid malignancies.6,7,9,17,18,20,37–41 However, some of these prognostic scores require extended analysis of differential blood cell count, which is not routinely measured in patients with primary PDAC undergoing resection.6–8,10,18,40,41 The PI involves CRP and WBC as prognostic biomarkers. CRP has demonstrated superior prognostic impact in survival estimation of cancer patients compared with WBC components and albumin.40,42 High CRP levels reflect the risk of cancer incidence and cancer-associated death.42,43 The PI and the (modified) Glasgow Prognostic Score, made up of CRP and albumin, are powerful prognostic tools in a variety of cancers compared with the neutrophil–lymphocyte ratio (NLR), the platelet-lymphocyte ratio (PLR), and the prognostic nutritional index (PNI).40,41 With regards to PDAC, neutrophilia in particular has been associated with pro-cancer effects.44 In the present analysis, a strong correlation between WBC and tumour stage was found, with higher WBC counts in patients with nodal-positive disease. These findings reflect the utility of leucocytes as valid biomarkers for patients with PDAC undergoing resection. Consequently, the combination of both markers, CRP and WBC, might most reliably reflect the inflammatory status of the patients allocated to surgery. Another advantage of the PI is its cost effectiveness and availability during initial routine blood tests.20 In contrast, scores, such as the neutrophil–lymphocyte ratio (NLR), the platelet-lymphocyte ratio (PLR), and the prognostic nutritional index (PNI), use parameters that need to be obtained by differential blood tests.
Previous analyses of PDAC specimens after neoadjuvant treatment have yielded conflicting results regarding the state of cancer-related inflammation. However, neoadjuvant treatment seems to induce an altered immune response that influences survival.28,30,31,45 We show that the PI’s prognostic strength is not impaired by neoadjuvant therapy. Of note, one might speculate to exclude patients with borderline resectable or locally advanced PDAC from this analysis due to the different treatment setting; however, in this study, we wanted to test the influence of concomitant factors (and neoadjuvant treatment as such) on the PI’s strength on survival prognostication. Still, in a subgroup analysis with primary resectable patients only (n = 307), the PI persisted as solid and strong independent factor for survival. Next to chemotherapy, further concomitant factors such as age, diabetes, smoking and high bilirubin levels common in the PDAC patient population, have been shown to interact with the immune- and inflammation cascade and thus might influence the PI’s prognostic strength.21–31 We demonstrate that the only factor that influences the PI’s strength for survival prognostication is the presence of a bile stent. In contrast to risk factors that are chronically present (age, diabetes, smoking), preoperative introduction of a bile stent fosters (incipient) cholangitis. Although patients who had a bile stent did not suffer from higher PI levels (compared with those without bile stent), bacterial overgrowth caused by the intervention maintains (chronic) inflammation, which on the one hand might not impair CRP and WBC levels but on the other hand hampers physical reserves and thus postoperative survival.46,47 However, despite the presence of PDAC-specific risk factors, progressive tumour mass (CA 19-9) as well as tumour stage, the PI is a reliable tool for preoperative survival prognostication in PDAC patients undergoing resection.
To our knowledge, this is the first study to assess the PI’s clinical utility for survival estimation in a selected cohort of patients with PDAC undergoing resection. The results indicate that the PI is a reliable tool in predicting disease-specific survival prior to surgery. In addition, the PI may perform better than other scores for survival prognostication, most likely due to the combination of CRP and WBC and its robustness against other concomitant factors. Nonetheless, this study is of retrospective nature and reflects an unicentre experience. Thus, the above findings require validation by a prospective, multicentre protocol.
Anzeige
In conclusion, the determination of the PI as a prognostic biomarker for systemic inflammatory activity offers an opportunity to identify patients at risk for poor survival prior to surgery. However, prospective multicentre studies are required to prove this concept.
Acknowledgements
Open access funding provided by Medical University of Vienna.
Disclosures
MG has received institutional research support from AstraZeneca, Roche, Novartis, and Pfizer, and has received lecture fees, honoraria for participation on advisory boards, and travel support from Amgen, AstraZeneca, Celgene, Eli Lilly, Invectys, Pfizer, Nanostring, Novartis, Roche, and Medison. He has served as a consultant for AstraZeneca and EliLilly, and an immediate family member is employed by Sandoz. None of the other authors have financial and personal relationships with individuals or organizations that could inappropriately influence their work.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit der Zeitschrift Die Chirurgie erhalten Sie zusätzlich Online-Zugriff auf weitere 43 chirurgische Fachzeitschriften, CME-Fortbildungen, Webinare, Vorbereitungskursen zur Facharztprüfung und die digitale Enzyklopädie e.Medpedia.
Bis 30. April 2024 bestellen und im ersten Jahr nur 199 € zahlen!
Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.
Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.
Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.
Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.
Update Chirurgie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.
Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.
